Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Avant Research Associates, LLC

Neither a doctor nor a teaching hospital

Research payments

$307,948

28 payments

Through program year 2025, Avant Research Associates, LLC is reported as receiving $307,948 in research payments, across 28 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $25 1
2024 Research $71,235 4
2023 Research $100,972 10
2022 Research $13,111 2
2021 Research $40,990 2
2020 Research $52,103 5
2019 Research $29,512 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $150,463 9 payments
  2. Celgene Corporation $124,577 13 payments
  3. AstraZeneca Pharmaceuticals LP $28,845 3 payments
  4. Chiesi USA, Inc. $3,328 2 payments
  5. Teva Pharmaceuticals USA, Inc. $736 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $86,550 4 payments
  2. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $60,757 2 payments
  3. Induction Study #1 - A Phase 3, Multicenter, Rando $34,962 1 payment
  4. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) $31,148 1 payment
  5. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $28,845 3 payments
  6. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) $26,002 4 payments
  7. Ph III Yellowstone CD OLE (RPC01-3204) (BMS Study Number: IM047-P17) $9,309 1 payment
  8. Ph III Yellowstone CD Maintenance (RPC01-3203) (BMS Study Number: IM047-P16) $8,250 1 payment
  9. A Phase 3, Multicenter, Open-Label Extension Study $6,029 1 payment
  10. Ph III Yellowstone CD OLE (RPC01-3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn s Disease $3,658 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record